omniture
瑞石生物医药有限公司 Reistone Biopharma Co. Ltd.

Latest News

Reistone Biopharma's oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for Atopic Dermatitis

SHANGHAI, Nov. 15, 2022 /PRNewswire/ -- Reistone Biopharma (Reistone), a leading biotech company f...

2022-11-15 21:00 2605

Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis

* SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical si...

2020-10-26 19:40 1429

Reistone Announces First Patient Dosed in a Phase II Global Study of SHR0302 JAK Inhibitor for Alopecia Areata

SHANGHAI, June 18, 2020 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone), a clinical s...

2020-06-19 09:16 1245